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Cytotoxic T lymphocytes (CTLs) play a critical role in the control of various cancers and infections, and therefore the molecular
mechanisms of CTL generation are a critical issue in designing antitumor immunotherapy and vaccines which augment the
development of functional and long-lasting memory CTLs. Interleukin (IL)-27, a member of the IL-6/IL-12 heterodimeric
cytokine family, acts on naive CD4+ T cells and plays pivotal roles as a proinﬂammatory cytokine to promote the early initiation
of type-1 helper diﬀerentiation and also as an antiinﬂammatory cytokine to limit the T cell hyperactivity and production of pro-
inﬂammatory cytokines. Recent studies revealed that IL-27 plays an important role in CD8+ T cells as well. Therefore, this article
reviews current understanding of the role of IL-27 in CD8+ T cell functions and generation of CTLs.
1.Introduction
A functional CD8+ T cell response is an essential component
of the adaptive immune response to various cancers, and
bacterial and viral pathogens [1]. Upon engagement with
antigen (Ag), naive CD8+ T cells rapidly expand and diﬀer-
entiate into eﬀector CD8+ T cells, producing cytokines such
as interferon (IFN)-γ and the eﬀector molecules, perforin
and granzyme B. Eﬀector cytotoxic T lymphocytes (CTLs)
play a key role in the host defense, using at least two distinct
mechanismstomediatedirectkillingoftargetcells.CTLslyse
targets by perforin-mediated release of granzyme B, which
is a serine protease to induce apoptosis, and also express
Fas ligand (FasL) to engage Fas on a target cell resulting in
apoptosis.
TheT-boxtranscriptionfactorT-betisamasterregulator
of type-1 helper (Th1) diﬀerentiation [2] and cell-mediated
immunity capable of controlling the expression of genes
encoding eﬀector molecules in CD4+ and CD8+ Tc e l l s
[3], as well as natural killer (NK) cells [4]. In addition to
regulating the eﬀector genes of cell-mediated immunity, T-
bet functions in the maturation and homeostasis of NK
T cells (NKT cells) and NK cells [4] and contributes to
the induction of CD8+ Tc e l lm e m o r y[ 5, 6]. Despite its
possible involvement in the development and function of
the cytotoxic lineages, there seems to be a substantial T-bet-
independent component of CD8+ Tc e l la n dN Kc e l le ﬀector
function and homeostasis [7]. Eomesodermin (EOMES) is
anotherT-boxtranscriptionfactorthatishighlyhomologous
to T-bet and is expressed in activated CD8+ Tc e l l sa s
well as resting and activated NK cells [7]. EOMES plays
a critical role during vertebrate development, and EOMES
deﬁciency in mice shows embryonic death [8]. Dominant
negative EOMES expression in CD8+ T cells results in loss-
of-function of CD8+ T cells, whereas ectopic expression of
EOMES was shown to induce expression of IFN-γ, perforin,2 Journal of Biomedicine and Biotechnology
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Figure 1: The IL-6/IL-12 heterodimeric cytokine family. IL-27 plays pivotal roles as a pro-inﬂammatory cytokine to promote the early
induction of Th1 diﬀerentiation and also as an anti-inﬂammatory cytokine to limit the T cell hyperactivity and production of pro-
inﬂammatory cytokines.
and granzyme B, suggesting that this transcription factor
is important in diﬀerentiation of naive CD8+ T cells into
eﬀector CTLs [7]. Furthermore, recent studies revealed that
CD8+ T cells deﬁcient in both T-bet and EOMES, but
not either one, fail to diﬀerentiate into functional killers
required for defense against lymphocytic choriomeningitis
virus (LCMV) [9]. Thus, T-bet and EOMES redundantly
activate a transcriptional network required for CD8+ Tc e l l
participation in defense against intracellular pathogens.
T-bet expression is induced by IFN-γ through activation
of signal transducer and activator of transcription (STAT)1
[10, 11]. In addition to IFN-γ and type I IFNs, STAT1
phosphorylation and T-bet expression can also be induced
by other cytokines including interleukin (IL)-27, an IL-6/IL-
12 family cytokine [12–14]. Several recent reports suggest
that IL-27 may play an important role in induction of
CD8+ T cell functions and generation of CTLs [15–21].
This review focuses on the critical role for IL-27 in CD8+
T cells.
2. The IL-6/IL-12 CytokineFamily
The IL-6/IL-12 cytokine family has a unique characteristic
that it is a heterodimeric cytokine composed of two diﬀerent
subunits (Figure 1)[ 22, 23]. IL-12 is composed of p35 and
p40 subunits; its receptor (R) consists of two subunits IL-
12Rβ1a n dβ2, and IL-12 activates STAT4, which binds to
cytoplasmic region of IL-12Rβ2[ 22]. The p40 subunit is
also covalently bound with an IL-12 p35-related protein
p19 to form IL-23 [24]. Receptor for IL-23 is composed
of one of IL-12R subunits IL-12Rβ1, and an IL-12Rβ2-
like receptor subunit designated IL-23R [25]. IL-23 activates
STAT3 and STAT4, and STAT3 activation is required for IL-
17 production by T cells with IL-23 [26]. IL-27 consists of
an IL-12 p35-related protein p28, and an IL-12 p40-related
protein, Epstein-Barr virus (EBV)-induced gene 3 (EBI3),
which has been previously identiﬁed as one of molecules
induced by EBV infection [27–29]. IL-27R is composed
of the IL-27Rα (WSX-1/T-cell cytokine receptor, TCCR),
which has a WSXWS sequence and is homologous to the
IL-12Rβ2 subunit, and gp130, a common receptor subunit
for IL-6 family cytokines [30]. EBI3 was previously reported
to associate with p35 as well to form the heterodimeric
molecule EBI3/p35, whereas its function had remained
unknown [31, 32]. Recently, the EBI3/p35 was demonstrated
to be produced by regulatory T (Treg) cells and contribute to
their suppressive activity [33, 34]. Therefore, it was named
IL-35, while its signaling cascade and its receptor have not
been identiﬁed yet.
Although IL-27 has been reported to activate STATs1–5,
several biological activities are attributed to STAT1 and/or
STAT3, which bind to distinct IL-27R subunits, IL-27Rα and
gp130, respectively (Figure 2)[ 12–14, 35, 36]. The contribu-
tion of other STATs such as STATs2, 4, and 5 largely remains
unknown. The role of IL-27 in regulating immune response
is complex with its stimulatory and inhibitory eﬀects act-
ing on various kinds of cells including T cells, B cells,
macrophages, and dendritic cell (DC) [37]. IL-27 plays a role
in the early induction of Th1 diﬀerentiation [12, 38, 39].
IL-27 up-regulates the expression of intercellular adhesion
molecule (ICAM)-1, T-bet and subsequent IL-12Rβ2, andJournal of Biomedicine and Biotechnology 3
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synergies with IL-12 in primary IFN-γ production [12, 13,
27, 39–41]. In contrast, IL-27 down-regulates the expression
of a Th2-speciﬁc transcriptional factor, GATA3 [14, 42].
In agreement with these in vitro studies, IL-27Rα-deﬁcient
mice have enhanced susceptibility to infection with several
intracellular pathogens [28, 38, 43]. However, IL-27Rα is not
essential to develop the protective Th1 responses [38, 43],
and recent studies revealed that IL-27 regulates not only pro-
inﬂammatory responses including the early initiation of Th1
responses, but also anti-inﬂammatory responses including
the suppression of cellular activation and pro-inﬂammatory
cytokine production in certain infections with Toxoplasma
gondii [44, 45]a n dTrypanosoma cruzi [46]. Moreover,
several lines of evidence demonstrated that IL-27 suppresses
Th17 diﬀerentiation and the development of experimental
autoimmune encephalomyelitis (EAE) [45, 47, 48]. IL-27
also induces the production of one of the immunosuppres-
sive cytokines, IL-10, by activated T lymphocytes, and IL-
10 is considered to be involved in the immunomodulatory
function of IL-27 [49–51]. In addition, it was recently
demonstrated that IL-27 together with transforming growth
factor (TGF)-β plays a dominant function in generating IL-
10-producing anti-inﬂammatory T regulatory type 1 (Tr1)
cells [52]. IL-27 drives the expansion and diﬀerentiation of
Tr1 cells by inducing three key elements, the transcription
factor c-Maf, the cytokine IL-21, and the costimulatory
receptor inducible costimulatory (ICOS) [53]. IL-27-driven
c-MafexpressiontransactivatesIL-21production,whichacts
as an autocrine growth factor for the expansion and/or
maintenance of IL-27-induced Tr1 cells, and IL-27-enhanced
ICOS expression further promotes IL-27-driven Tr1 cells.
3. IL-27 Augments Antigen-Speciﬁc
CTL Generation
The eﬀect of IL-27 on CD8+ T cells in vitro was investigated
by us [15]. In a manner similar to CD4+ T cells [12–
14, 35, 36, 40], IL-27 activated STATs1–5, and augmented
the expression of not only T-bet and IL-12Rβ2 but also
eﬀector molecules such as granzyme B, and perforin in
naive CD8+ T cells stimulated with anti-CD3 and anti-
CD28. IL-27 induced synergistic IFN- γ production with
IL-12 and proliferation of naive CD8+ T cells. IL-27 also
enhanced proliferation of CD4+ T cell-depleted spleen cells
stimulated by allogeneic spleen cells and augmented the
generation of CTL. Both T-bet and EOMES are required
to generate functional CTLs and to induce their eﬀector
molecules such as perforin and granzyme B [5–7, 9].
Therefore, the role of STAT1 and T-bet for the IL-27-
mediated functions in CD8+T cells was examined using
deﬁcient mice in STAT1 and T-bet [15]. In STAT1-deﬁcient
naive CD8+ T cells, IL-27-induced proliferation was not
reduced but synergistic IFN-γ production with IL-12 was
diminished with decreased expression of T-bet, IL-12Rβ2,
granzyme B, and perforin. In T-bet-deﬁcient naive CD8+
T cells, IL-27-induced proliferation was hardly reduced but
synergistic IFN-γ production with IL-12 was diminished4 Journal of Biomedicine and Biotechnology
with decreased expression of IL-12Rβ2, granzyme B and
perforin. However, IL-27 still augmented the generation
of CTL from T-bet-deﬁcient CD4+ T cell-depleted spleen
cells stimulated by allogeneic spleen cells with increased
EOMES and granzyme B expression. Thus, IL-27 induces the
generationoffunctionalCTLsbyaugmentingbothT-betand
EOMES.
There are a number of evidences showing that CTLs play
a central role in the clearance of pathogenic viruses [54]. In
case of hepatitis C virus (HCV) infection, vigorous HCV-
speciﬁc CTL responses exist in the persons resolving acute
HCV infection, and enhancement of HCV-speciﬁc CTL
induction in HCV-infected individuals is considered to be
one of the strategies to clear the virus [55]. DNA vaccination
has been proven to be a useful strategy for inducing both
humoral and cellular immune responses, and safely mimics
the eﬀect of live, attenuated virus-based vaccine to generate a
long-lasting CTL response [56]. Therefore, adjuvant eﬀects
of IL-23 and IL-27 were evaluated by the prime-boost
immunization consisting of priming and the ﬁrst boosting
with the HCV-core expression plasmid, followed by a second
boosting with recombinant adenovirus expressing HCV core
for induction of HCV core-speciﬁc CTLs in HLA-A∗0201
transgenic BALB/c mice [16]. To circumvent uneven gene
expression of the two subunits, genetically linked, single-
chain (sc)IL-12, scIL-23, and scIL-27 were used in theses
experiments.CoadministrationofeitheranIL-23oranIL-27
expression plasmid, as well as an IL-12 expression plasmid,
in a prime-boost immunization enhanced induction of
HCV-speciﬁc CTLs and led to dramatic increases in the
numbers of IFN-γ-producing, HCV-speciﬁc CD8+ cells
[16]. Furthermore, preinjections of IL-12, IL-23, or IL-27
expression plasmids before immunization resulted in great
increases in the number of IFN-γ-producing, HCV-speciﬁc
CD8+ cells in response to immunization with recombinant
adenovirus. These data revealed that both IL-23 and IL-27,
as well as IL-12, have potent adjuvant activity for induction
of epitope-speciﬁc CTL.
4. IL-27 InducesAntitumor Activityvia
Augmenting Tumor-Speciﬁc CTL Generation
IL-12 is considered to be one of the most eﬀective cytokines
against various tumors, because it activates NK cell, pro-
motes Th1 polarization, and, thereby, promotes cellular
immune responses and proliferation of CTL [57, 58]. The
promisingdataobtainedinthepreclinicalmodelshaveraised
much hope that IL-12 could be a powerful therapeutic agent
against cancers [57, 58]. However, excessive clinical toxicity
andmodestclinicalresponseintheclinicaltrialshavelimited
the IL-12 therapy [59]. Since IL-27 has several similarities to
IL-12, it plays a role in the initiation of Th1 diﬀerentiation
[12, 39, 41], and enhances generation of CTL [15, 16]a s
described above, we evaluated the antitumor activity of IL-
27 and demonstrated for the ﬁrst time that IL-27 has a
potent antitumor activity [17]. Since then, IL-27 has been
evaluated in various preclinical tumors, and a number of
reports revealed that IL-27 exerts potent antitumor eﬀects
against various tumor models such as colon carcinoma [17,
20, 21], neuroblastoma [18], melanoma [60–62], head and
neck squamous cell carcinoma [63], and lung cancer [64]
via diﬀerent mechanisms depending on the characteristic
of each tumor. These include mechanisms through not
only CD8+ T cells [17, 18, 21], but also NK cells [21,
61, 63], antiangiogenic activity [60], direct antiproliferative
activity [62], and suppression of cyclooxygenase-2-mediated
activities [64].
Hisada et al. have ﬁrst evaluated the antitumor activity
of IL-27 against a murine tumor model of colon carcinoma
colon26(C26)[17].C26tumorcells,whichweretransduced
with the linked scIL-27 cDNA and became secreting IL-27
(C26-IL-27), exhibited a minimal tumor growth in vivo,
and all mice inoculated with these tumor cells survived
with a complete tumor remission. Inoculation of mice with
C26-IL-27 tumors induced enhanced IFN-γ production and
CTL activity against C26 tumors in spleen cells. Recovered
mice from the inoculation showed a tumor-speciﬁc pro-
tective immunity to the following challenge with parental
C26 tumors. The antitumor activity of IL-27 was almost
diminished in nude mice, and depletion of CD8+ T cells and
neutralization of IFN-γ in immunocompetent mice reduced
the antitumor activity. These results suggest that IL-27 has
potent abilities to induce tumor-speciﬁc antitumor activity
and protective immunity, which is mediated through mainly
CD8+ T cells. Moreover, the antitumor activity was greatly
reduced in T-bet-deﬁcient mice, but not in STAT4-deﬁcient
mice [17]. Since STAT4 is essential for IL-12 to show its bio-
logical activities [65, 66], this result implies that IL-27 exerts
the antitumor activity even in the absence of endogenous
IL-12. This is consistent with the fact that IL-27 induces
Th1 diﬀerentiation even in the absence of IL-12 in vitro
[39, 41]. Of note, during the IL-27 treatment, any apparent
adverse eﬀects such as, splenomegaly and liver injury with
elevated serum glutamic-oxaloacetic transaminase (GOT)
and glutamic-pyruvic transaminase (GPT) activities and
intensive mononuclear cell inﬁltration into liver were not
observed, which were seen with IL-12 treatment [67–69].
Similar CD8+ T cell-mediated antitumor eﬀects were also
reported by Chiyo et al. using C26 transduced with the
heterodimeric IL-27 cDNA (p28-IRES-EBI3) [20, 21]. Taken
together, these studies suggest that IL-27 exerts CD8+ Tc e l l -
mediated antitumor eﬀects.
Salcedo et al. have also reported that IL-27 exerts
CD8+ T cell-mediated potent antitumor activity using other
tumor model, TBJ neuroblastoma, which was engineered
to overexpress scIL-27 (TBJ-IL-27) [18]. TBJ-IL-27 tumors
showed markedly delayed growth compared with control
mice, and complete durable tumor regression was observed
in almost all of mice bearing either subcutaneous or
orthotopic intraadrenal tumors, and in half of mice bear-
ing induced metastatic disease. Consistent with the above
other reports [17, 20, 21], the majority of mice cured
of TBJ-IL-27 tumors were resistant to tumor rechallenge.
Moreover, TBJ-IL-27 tumors were heavily inﬁltrated by
CD8+ T cells. Draining lymph node-derived lymphocytes
from mice bearing subcutaneous TBJ-IL-27 tumors were
primed to proliferate more readily when cultured ex vivoJournal of Biomedicine and Biotechnology 5
with anti-CD3/anti-CD28 compared with lymphocytes from
mice bearing control tumors, and to secrete higher levels
of IFN-γ. In addition, marked enhancement of local IFN-
γ gene expression and potent up-regulation of cell surface
major histocompatibility complex (MHC) class I expression
were noted within TBJ-IL-27 tumors compared with control
tumors. Similar direct eﬀects of IL-27 on tumors to up-
regulateMHCclassImoleculewerereported[62].Moreover,
depletion experiments using speciﬁc antibodies revealed that
the induction of TBJ tumor regression by IL-27 is mediated
via mechanisms that are critically dependent on CD8+,b u t
not CD4+T cells or NK cells. Thus, CD8+ T cells are critically
involved in the exertion of antitumor activity by IL-27.
5. Endogenouse IL-27 inCD8+ TC ell sI s
Important for CTL Generation
IL-27 thus facilitates tumor-speciﬁc CTL induction against
various tumors. However, IL-27 also suppresses cytokine
production of lymphocytes and Ag-presenting function of
DCs [70]. Therefore, to examine the role of endogenous IL-
27 in generation of CTL and antitumor immunity, IL-27-
mediated antitumor eﬀects were examined using IL-27Rα
(WSX-1)-deﬁcient mice [38]. In IL-27Rα-deﬁcient mice, in
which host cells cannot receive IL-27-mediated signaling,
inoculated with B16F10 melanoma cells, tumor growth was
higher than in wild-type (WT) mice [19]. These results are
consistent with the fact that IL-27 favors establishment of
antitumor immunity as described above [17, 18, 20, 21].
Failure of successful inhibition of tumor growth in IL-27Rα-
deﬁcient mice could be attributable to impaired generation
of CTL or impaired function of other types of cells, such as
Ag-presenting cells (APCs). To address this issue, tumor Ag
TRP2 peptide-pulsed WT DCs were adoptively transferred
into WT or IL-27Rα-deﬁcient mice and examined the eﬀects
on tumor growth [19]. In WT mice, transfer of peptide-
pulsed DCs induced further protective immunity against
B16F10 tumor as compared with the PBS-treated control
W Tm i c e .E v e ni nI L - 2 7 R α-deﬁcient mice, transfer of WT
DCs pulsed with Ag peptide conferred protective immunity.
However, IL-27Rα-deﬁcient mice transferred with DCs still
showed excessive growth of tumors as compared with DC-
transferred WT mice. These data indicate that the impaired
generation of antitumor immunity in IL-27Rα-deﬁcient
mice may be attributable to eﬀector populations but not
APCs. Consistent with this idea, IL-27Rα-deﬁcient mice
with WT DC transfer generated still lower killing activity
than WT mice with DC transfer, although DC transfer
induced tumor-speciﬁc killing activity over PBS control
[19]. Perforin expression in generated CTLs from IL-27Rα-
deﬁcient mice was also lower than in those from WT mice,
which is consistent with the previous report [15]. Moreover,
DC transfer augmented expression of perforin by generated
CTLs from WT mice, while there was little augmentation
by DC transfer in CTLs from IL-27Rα-deﬁcient mice. These
resultsdemonstratethatendogenousIL-27,throughIL-27Rα
signaling, favors generation of CTL with enhanced perforin
expression. Of note, when transferred into tumor-bearing
mice, IL-27Rα-deﬁcient DCs pulsed with Ag peptide was
more potent than WT DCs in tumor growth inhibition
and generation of CTLs [19]. This indicates that IL-27Rα
signaling has suppressive eﬀects on DC function, as reported
previously [70]. Thus, endogenous IL-27 promotes tumor
speciﬁc CTL generation in CD8+ T cells, while suppressing
APCfunctioninDCs,duringgenerationoftumorimmunity.
6. IL-27R SignalingIs Indispensablefor
T-bet-Dependent IFN-γ Production in
CD8+ TC ell s
CD8+ T cells are one of the major sources of IFN-γ,a
key eﬀector cytokine in immune responses against many
viruses and protozoa [71]. The diverse eﬀects of IFN-γ on
numerous immune cells are mediated through the widely
expressedIFN-γ RandtheactivationofSTAT1[71].InCD4+
Tcells,STAT1appearstobecriticalfortheactivationofT-bet
andIFN-γ,suggestinganIFN-γ-dependentpositivefeedback
loop, that is, IFN-γ-dependent STAT1-mediated induction
of IFN-γ [10, 11]. However, STAT1 can also be activated by
other cytokines, including IL-27. To examine the expression
of IFN-γ by CD8+ T cells directly in vivo, Yeti IFN-γ reporter
mice were used to bypass the need for in vitro restimulation
[72, 73]. In Yeti mice, the IFN-γ-YFP reporter is faithfully
expressed only under conditions known to induce IFN-γ,
and the reporter ﬂuorescence intensity correlates directly
with both the abundance of IFN-γ transcripts and the
production of IFN-γ upon restimulation [72, 73]. Using the
Yeti IFN-γ reporter mice, the CD8+ T cell-intrinsic roles of
IFN-γ R, IL-27R, and T-bet for IFN-γ expression in response
to viral and protozoan infection were examined by direct
in vivo staining [74]. To directly compare T-bet-deﬁcient
or IFN-γ R-deﬁcient T cells with WT T cells in the same
animal in a T-bet- or IFN-γ R-suﬃcient environment, mixed
bone marrow (BM) chimeras in which lethally irradiated
C57BL/6 mice (CD45.1 or CD45.2) were reconstituted with
BM from WT Yeti mice (CD45.1) mixed 1:1 with either T-
bet-deﬁcient Yeti or IFN-γ R-deﬁcient Yeti CD45.2 donors.
Mixed T- bet-deﬁcient/WT BM chimeras were then infected
with inﬂuenza virus, Sendai virus, or Toxoplasma gondii,a n d
various organs were analyzed for IFN-γ response within the
population of Ag-speciﬁc cells generated by the respective
donor BM using MHC class I tetramers speciﬁc for each
Ag. Very few Ag-speciﬁc T-bet-deﬁcient CD8+ Tc e l l si n
respectively infected mixed BM chimeras expressed IFN-
γ, while the vast majority of Ag-speciﬁc WT cells were
YFP+ [74]. Importantly, the defective IFN-γ response was
not due to a failure of the T-bet-deﬁcient compartment
to prime, expand, or disseminate a population of Ag-
speciﬁc CD8+ T cells, because the frequency of Ag-speciﬁc
cells was comparable to that of the internal WT control
[74]. Although T-bet is reportedly induced by the IFN-γ
R/STAT1 pathway [10, 11], IFN-γ expression in IFN-γ R-
deﬁcient CD8+ T cells was not impaired in mixed IFN-γ
R-deﬁcient/WT BM chimeras infected with inﬂuenza virus
or Sendai virus as compared with the internal WT control
cells. These observations demonstrate that direct IFN-γ6 Journal of Biomedicine and Biotechnology
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Figure 3: IL-27 plays a pivotal role in CD8+ T cell functions and generation of CTLs. In naive CD8+ T cells, IL-27 activates STAT1 and
induces expression of T-bet and EOMES, which are critical transcriptional factors for generation of CTL by transcriptionally up-regulating
IFN-γ and eﬀector molecules such as perforin and granzyme B. IL-27 also induces not only proliferation but also SOCS3 expression to limit
the excessive proliferation mediated through gp130 of IL-27R.
R signaling is dispensable for the priming, expansion, or
dissemination of Ag-speciﬁc CD8+ T cells. However, these
results are in striking contrast to a recent adoptive transfer
study suggesting that direct IFN-γ R signaling is critical for
the expansion of a CD8+ T cell response during acute viral
infection [75].
Since T-bet reportedly functions downstream of STAT1
[10, 11, 13, 76] and the IFN-γ R is dispensable for T-bet-
dependent IFN-γ expression, it was then explored whether
the STAT1-activating IL-27R signaling regulates T-bet-
dependent IFN-γ expression by CD8+ T cells in vivo [74].
Mixed BM chimeras were generated from IL-27Rα (TCCR)-
deﬁcient Yeti (CD45.2) and WT Yeti (CD45.1) donors
(IL-27Rα-deﬁcient/WT) and infected with inﬂuenza virus
or Toxoplasma gondii. The frequency of IFN-γ-expressing
cells was profoundly reduced within Ag-speciﬁc IL-27Rα-
deﬁcient CD8+ T cells as compared with the internal WT
control [74]. The IFN- γ response of activated CD8+ Tc e l l s
was similarly impaired in the IL-27Rα-deﬁcient population
of IL-27Rα-deﬁcient/WT mixed BM chimeras, while the
frequency of activated cells was not reduced. Taken together,
these studies suggest that T-bet is critical for the in vivo IFN-
γ production by CD8+ T cells upon infection of mice with
diverse pathogens. Whereas IFN-γ R signaling is dispensable
for the T-bet-dependent IFN-γ production, direct IL-27R
signaling is critical for the IFN-γ response in CD8+ T cells.
7.CD8+ T Cell ProliferationIs Regulated
by SOCS3 through Inhibitionof IL-27R
Signaling
Suppressor of cytokine signaling (SOCS) proteins regulates
theintensityanddurationofcytokineresponses[77].SOCS3
isexpressedinperipheralTcells,andrecentreportshavesug-
gested that overexpression of SOCS3 modulates Ag- and/or
costimulation-induced T-cell activation [78]. Other studies
inwhichSOCS3wasdeletedintheliverormacrophageshave
also shown SOCS3 to be a critical regulator of IL-6 signals
[79–81]. On a molecular level, this has been attributed to
the binding of SOCS3 to phosphorylated Tyr757 (Y757)
of the gp130 receptor chain, thereby bringing SOCS3 into
proximity to and then inhibiting receptor-associated JAKs
[82]. The association of SOCS3 with gp130, the common
receptor subunit for the IL-6 family of cytokines, suggests
that SOCS3 may regulate activities of other members of this
family. IL-27, one of these gp130 ligands, induces SOCS3
expression [36, 83, 84], and it was shown previously that
IL-27 suppresses IL-2 production and the development of
Th17cells[36,45,47,83–85].Therefore,itwasproposedthat
SOCS3 mediates these inhibitory eﬀects of IL-27 [47, 83].
However, studies with SOCS3-deﬁcient T cells have shown
that SOCS3 is not essential for IL-27-induced suppression of
Th17 diﬀerentiation [45, 86].Journal of Biomedicine and Biotechnology 7
To investigate the role of SOCS3 in T-cell function
and homeostasis in vivo, conditional SOCS3-deﬁcient mice,
in which the SOCS3 gene was deleted speciﬁcally within
T and NKT cells, were used [86, 87]. SOCS3-deﬁcient T
cells were revealed to be hyperproliferative in response to
a TCR stimulus [88]. This eﬀect was seen in both CD4+
and CD8+ T cells but was most pronounced in SOCS3-
deﬁcient CD8+ T cells. Hyperproliferation in the absence of
SOCS3 is consistent with previous studies that showed that
overexpression of SOCS3 in T cells results in reduced pro-
liferation in response to TCR [89] and antigenic stimulation
[90]. However, SOCS3-deﬁcient T cells responded normally
toTCRstimulationincombinationwithcostimulation(anti-
CD3 plus anti-CD28), which suggests that costimulatory
pathways are unaﬀected by the absence of SOCS3 [88].
In addition, signaling pathways downstream of the TCR
including calcium-signaling pathways were activated to a
normal intensity and duration in the absence of SOCS3,
although responses to TCR ligation were enhanced [88].
Thus, T-cell defects are most probably caused by enhanced
cytokine signaling in the absence of SOCS3. Previous studies
have shown that SOCS3 regulates gp130 cytokines [79–
81, 91]. Indeed, CD8+T cells from gp130Y757F/Y757F mice,
which lack the SOCS3-binding site on gp130 [92], also
proliferated strongly in response to TCR ligation despite
the TCR-signaling pathways being unaﬀected in these cells
[88]. This result suggests that hypersensitivity to a gp130
cytokine drives the hyperproliferative phenotype of SOCS3-
deﬁcient T cells. Consistent with the idea, SOCS3-deﬁcient T
c e l l sh a dp r o l o n g e dS T A Ta c t i v a t i o ni nr e s p o n s et ob o t hI L -
6 and IL-27, the main gp130 cytokines that act on T cells
[88]. While the absence of IL-6 had no eﬀect, inhibition
of IL-27 limited anti-CD3-induced proliferation in CD8+
T cells. Taken together, these data suggest that enhanced
proliferation to TCR ligation by SOCS3-deﬁcient CD8+T
cells is not caused by aberrant TCR-mediated signaling,
but, rather, by increased IL-27R-mediated signaling in the
absence of SOCS3 [88].
8. Concluding Remarks
Collectively, by directly acting on naive CD8+ T cells, IL-27
activates STAT1 and induces two related T-box transcription
factors, T-bet and EOMES, critical for induction of eﬀector
molecules such as perforin and granzyme B to generate
functional CTLs (Figure 3). Consistent with the in vitro
results, DNA vaccination with IL-27 increases the numbers
of IFN-γ-producing Ag-speciﬁc CD8+ T cells in vivo, and
IL-27-transduced tumor cells show CD8+ T cell-mediated
antitumor activity via augmentation of IFN-γ production
and tumor-speciﬁc CTL generation. Moreover, endogenous
IL-27 promotes CTL generation with enhanced perforin
expression, while it suppresses APC function in DCs due
to its anti-inﬂammatory functions, during generation of
antitumor immunity. Endogenous IL-27R signaling, but
not IFN-γR signaling, is also required for T-bet-dependent
IFN-γ production by CD8+ T cells upon infection with
various pathogens. Moreover, IL-27 together with TCR
stimulation induces not only proliferation but also SOCS3
expression to control excessive proliferation in CD8+ T
cells. Thus, the recent studies as described in the present
review clearly indicate that IL-27 may have a nonredundant
role in induction of CD8+ T cell functions and generation
of functional CTLs against various tumors and infectious
pathogens. Since IL-27 plays pivotal roles in not only the
early induction of Th1 diﬀerentiation but also the generation
of CTL, leading to augmentation of type 1 cell-mediated
immunity, IL-27 could be an attractive candidate as an
agent applicable to the immunotherapy against cancers and
pathogens.
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